22-05-2023

hema.to closes its seed round

We closed our €3.6M round, led by Elaia Partners

End of May, we closed our seed round with Elaia Partners, heal capital and HTGF to bring precision diagnostics to immune medicine. Anne-Sophie Carrese says, about the deal: "We have been convinced by the founding team, composed of three former entrepreneurs from the same company, with three PhD profiles, at a stage where they are going to scale their go to market, which is coherent with our deep tech seed investment thesis", Managing Partner at Elaia Partners. See tech.eu's press release here.

15-10-2022

hema.to is FDA compliant

In record time ...

.. we've achieved FDA-compliance (as a class I device) less than four months after receiving our CE mark. This was made possible by the professionalism and dedication of our team, but in particular by our US regulatory partner QServe Group, and our contact Jennifer Hadfield (left in picture), and our EU regulatory partner Be-on-Quality. The picture shows Aleks and Jennifer registering our device; the following day the FDA sent us the good news.

20-09-2022

Clinical study published

Clinical trial reveals hema.to is faster and better

We're incredibly proud to share that hema.to has been clinically validated in an international, four-center clinical trial! Blood cancer diagnoses weren't just twice as fast, they were made with 8% more sensitivity and 10% more specificity when made with the help of our beautiful, easy-to-use decision-support software. You can download the press release here.

14-07-2022

Medical Valley first prize

hema.to won the first prize ...

... at the Medical Innovation Night in Nürnberg, where we pitched hema.to in front of an audience an an excellent jury consisting of Medical Valley EMN e. V., Siemens Healthineers, aescuvest, GWQ ServicePlus AG, IONOS andFraunhofer IIS. We'll be using our E20k prize money to explore partnerships with GWQ and Siemens Healthineers.

26-05-2022

hema.to receives its CE mark

After months of hard work ...

... we are now compliant with the IVDD. We conform to ISO 13485 (quality management), ISO 14971 (risk management), ISO 62366 (usability), ISO 62304 (software life-cycle management) and IEC 82304 (health software).

Our publications

hema.to speeds up diagnostic workflow and improves quality
CLINICAL STUDY WHITE PAPER
September 20, 2022

hema.to speeds up diagnostic workflow and improves quality

We're incredibly proud to share that hema.to has been clinically validated in an international, four-center clinical trial! Blood cancer diagnoses weren't just twice as fast, they were made with 8% more sensitivity and 10% more specificity when made with the help of our beautiful, easy-to-use decision-support software. You can download the white paper here.

Knowledge transfer enhances performance
CELL PATTERNS PAPER
September 17, 2021

Knowledge transfer enhances performance

... as shown by Nanditha Mallesh and co-authors in this Cell Patterns paper. In this collaboration between the hema.to team, the Munich Leukemia Lab, Charité and additional renowned university clinics, we showed that data from multiple labs can be combined to increase the clinical performance of AI models for each lab.

Deep learning can classify blood cancer on an expert level
CYTOMETRY A PAPER
June 9, 2020

Deep learning can classify blood cancer on an expert level

... as shown by the hema.to team in collaboration with several experienced hematologists and the university of Bonn in this Cytometry A paper. With this paper, Zhao et al. have shown deep learning can be used to aid the routine clinical workflow using cytometry data.

Knowledge transfer enhances performance
BLOOD PAPER II
November 13, 2019

Knowledge transfer enhances performance

... as shown by Nanditha Mallesh and co-authors in this 2019 Blood paper. With this paper, we showed that improvement of diagnostic performance is generated by combining multiple datasets, an approach we call "knowledge transfer".

Neural nets provide highly reliable diagnostic support in a routine setting
BLOOD PAPER I
November 13, 2019

Neural nets provide highly reliable diagnostic support in a routine setting

... as shown by a collaboration between hema.to, the Munich Leukemia Lab and the University of Bonn in this 2019 Blood paper. This paper shows that AI can support hematologists in their routine workflows for blood cancer diagnosis by providing highly reliable recommendations.

Frequently Asked Questions

See more FAQ
What training resources are available for hema.to?
What kind of support does hema.to offer?
Can I adjust the results after the automated data analysis?
Should I use a specific cytometer / panel / workflow?
How many files per disease do the algorithms need in order to be trained?